Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companiesnews2025-03-13T14:50:24+00:00March 13th, 2025|Endpoints News|
Updated: Endo and Mallinckrodt to merge in $6.7B dealnews2025-03-13T11:13:19+00:00March 13th, 2025|Endpoints News|
Mallinckrodt and Endo exploring a $7B merger — reportnews2025-03-12T19:48:21+00:00March 12th, 2025|Endpoints News|
Ono licenses rare blood disease drug from Ionis for $280M upfrontnews2025-03-12T10:34:49+00:00March 12th, 2025|Endpoints News|
Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3Bnews2025-03-12T08:10:30+00:00March 12th, 2025|Endpoints News|
Endo sells international business for $84Mnews2025-03-11T14:26:38+00:00March 11th, 2025|Endpoints News|
Bristol Myers buys out cell therapy partner 2seventy bionews2025-03-11T07:13:39+00:00March 11th, 2025|Endpoints News|
Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibodynews2025-03-10T11:20:53+00:00March 10th, 2025|Endpoints News|
Exclusive: RNA delivery startup strikes partnerships with J&J, Daiichi Sankyonews2025-03-10T11:00:37+00:00March 10th, 2025|Endpoints News|
How bluebird’s buyout offer went from $100M upfront to $29Mnews2025-03-07T18:25:38+00:00March 7th, 2025|Endpoints News|
